Efficacy of Rituximab on Refractory Organ Involvements in Granulomatosis with Polyangiitis: A Systematic Review of Case Reports

Overview

Journal Curr Rheumatol Rev

Publisher Bentham Science Publishers

Specialty Rheumatology

Date 2023 Nov 1

PMID 37907486

Authors

Hamed Hajishah

Mohammad Javad Amini

Amir Shayan Chadeganipour

Seyyed Amirhossein Salehi

Danial Kazemi

Affiliations

Soon will be listed here.

Abstract

Introduction: Granulomatosis with polyangiitis (GPA) is a type of Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) characterized by necrotizing vasculitis affecting small and medium-sized blood vessels. GPA affects various organs, with respiratory tract, vasculitis and glomerulonephritis being the most common triad. Remission induction and maintenance therapy for GPA traditionally involves corticosteroids and cyclophosphamide. However, treatment with rituximab, a monoclonal antibody that depletes B-cells involved in autoimmune disease, has been successful in inducing remission in several studies. The purpose of this systematic review was to investigate the efficacy of rituximab in treating various clinical manifestations of GPA.

Methods: In adherence to PRISMA guidelines for systematic reviews and meta-analyses, we carried out a comprehensive review to investigate the effectiveness of rituximab on particular organ involvement in GPA. We searched three databases (PubMed, Scopus, and Embase) up until November 6, 2022, for case reports on the topic. To ensure all relevant studies were included, we manually screened the first 50 pages of Google Scholar's search results.

Results: The review identified a total of 64 case reports and a case series of 113 cases, highlighting the effectiveness of rituximab in treating refractory organ involvement in GPA. The review also analyzed the effectiveness of rituximab in treating ocular, CNS, cardiac, pulmonary, cutaneous, gastrointestinal, renal, and other organ involvements in GPA.

Conclusions: Our results indicated that rituximab can be a promising therapy for treating specific clinical manifestations of several organ involvements. However, more research is needed to determine the long-term efficacy of rituximab in treating GPA.

References

Geetha D, Jefferson J . ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2019; 75(1):124-137. DOI: 10.1053/j.ajkd.2019.04.031. View

Kubaisi B, Abu Samra K, Foster C . Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations. Intractable Rare Dis Res. 2016; 5(2):61-9. PMC: 4869584. DOI: 10.5582/irdr.2016.01014. View

Hunter R, Welsh N, Farrah T, Gallacher P, Dhaun N . ANCA associated vasculitis. BMJ. 2020; 369:m1070. PMC: 7179255. DOI: 10.1136/bmj.m1070. View

Emer J, Claire W . Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol. 2010; 2(5):29-37. PMC: 2924133. View

Raffray L, Guillevin L . Rituximab treatment of ANCA-associated vasculitis. Expert Opin Biol Ther. 2020; 20(8):899-910. DOI: 10.1080/14712598.2020.1748597. View

McKinney E, C Willcocks L, Broecker V, Smith K . The immunopathology of ANCA-associated vasculitis. Semin Immunopathol. 2014; 36(4):461-78. PMC: 4118034. DOI: 10.1007/s00281-014-0436-6. View

Bellos I, Boletis I, Lionaki S . A Meta-Analysis of the Safety and Efficacy of Maintenance Therapies for Antineutrophil Cytoplasmic Antibody Small-Vessel Vasculitis. Kidney Int Rep. 2022; 7(5):1074-1083. PMC: 9091778. DOI: 10.1016/j.ekir.2022.02.020. View

Hassan R, Gaffo A . Rituximab in ANCA-Associated Vasculitis. Curr Rheumatol Rep. 2017; 19(2):6. DOI: 10.1007/s11926-017-0632-1. View

Keogh K, Ytterberg S, Fervenza F, Carlson K, Schroeder D, Specks U . Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2005; 173(2):180-7. PMC: 2662987. DOI: 10.1164/rccm.200507-1144OC. View

10.

Luqmani R, Bacon P, Moots R, Janssen B, Pall A, Emery P . Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994; 87(11):671-8. View

11.

Seo P, Specks U, Keogh K . Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol. 2008; 35(10):2017-23. View

12.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland A, Provan D . Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006; 45(11):1432-6. DOI: 10.1093/rheumatology/kel098. View

13.

Lovric S, Erdbruegger U, Kumpers P, Woywodt A, Koenecke C, Wedemeyer H . Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant. 2008; 24(1):179-85. DOI: 10.1093/ndt/gfn430. View

14.

Taylor S, Salama A, Joshi L, Pusey C, Lightman S . Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009; 60(5):1540-7. DOI: 10.1002/art.24454. View

15.

Khan A, Lawson C, Quinn M, Isdale A, Green M . Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab. Int J Rheumatol. 2010; 2010:846063. PMC: 2964912. DOI: 10.1155/2010/846063. View

16.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

17.

Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C . Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015; 13(3):147-53. DOI: 10.1097/XEB.0000000000000054. View

18.

Kenny G, Holl-Ulrich K, Fulcher T, McElnea E, Kavanagh E, Moriarty H . Successful reconstruction of an ocular defect resulting from granulomatosis with polyangiitis, following treatment with rituximab. Am J Ophthalmol Case Rep. 2018; 10:240-243. PMC: 5956741. DOI: 10.1016/j.ajoc.2018.03.014. View

19.

Avshovich N, Boulman N, Slobodin G, Zeina A, Rosner I, Rozenbaum M . Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement. Isr Med Assoc J. 2009; 11(9):566-8. View

20.

Baslund B, Wiencke A, Rasmussen N, Faurschou M, Toft P . Treatment of orbital inflammation with rituximab in Wegener's granulomatosis. Clin Exp Rheumatol. 2012; 30(1 Suppl 70):S7-10. View